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Abstract. the effects of the egFr inhibitor Iressa on develop-
ment of urinary bladder cancers induced by hydroxybutyl(butyl)
nitrosamine (oH-BBn) in rats were examined. Iressa treatment 
(4.5 or 1.5 mg/kg BW/day) beginning one week after the last 
dose of oH-BBn decreased the occurrence of large (>200 mg) 
bladder cancers at termination of the study by 75 and 52%, 
respectively. treatment with Iressa (10 mg/kg BW/day) begin-
ning one week or three months (delayed initiation) after the last 
dose of OH-BBN also significantly increased tumor latency 
and decreased the incidence of palpable bladder cancers. In the 
delayed initiation study, microscopic cancers already existed 
when treatment was initiated; implying that the effects of 
Iressa occur late in tumor progression. potential pharmacody-
namics and/or efficacy biomarkers modulated by short-term 
exposure (5 day) to Iressa (10 mg/kg BW/day) were determined 
in palpable bladder lesions by using three different approaches: 
i) direct immunohistochemical examination of egFr related 
proteins; which showed that phosphorylated egFr, AKt 
and erK were significantly decreased; ii) measurement of 
protein expression by two dimensional gel electrophoresis and 
tandem mass spectrometry. this showed that the Annexin 
A2, MAp kinase kinase and nucleolin (all proteins associated 
with the VegF pathway) were decreased in treated tumors; 
and iii) measurement of gene expression determined in gene 
microarrays demonstrated that numerous pathways were 
markedly altered by Iressa treatment. In particular, cell cycle 
genes related to the anaphase protein complex (Apc) pathway, 
including cDc 20, cyclin B1, BUB1 and both of the Aurora 
kinases, were significantly decreased.
Introduction
the oH-BBn induced urinary bladder cancer model has been 
used to screen for potential chemopreventive agents (1,2). 
the model yields invasive bladder cancers with most tumors 
being pathologically classified as transitional cell carcinomas 
(tcc). the resulting tumors show various protein changes; 
e.g., increased levels of survivin and gst pi, and decreased 
levels of FHIt (3). these changes are often observed in 
human bladder tumors as well. More recently, we have exam-
ined gene expression in these tumors by microarray analysis, 
and have found a wide variety of genes to be overexpressed; 
including cyclin D1, pcnA, the calcium binding proteins 
s-100 (4,5), Annexin and numerous genes associated with 
the egFr pathway (4). In fact, a recent paper implied that the 
tumors which form in the rat urinary bladder cancer model 
are similar to invasive bladder cancers in humans when evalu-
ated by gene arrays (5).
Among the genes found to be overexpressed were those 
associated with the egFr pathway. previous studies in humans 
have shown overexpression of phosphorylated egFr in many 
urinary bladder tumors (6,7). these small molecule inhibitors 
(Iressa and erlotinib) function as competitive inhibitors of 
egFr autophosphorylation at the AMp binding site and 
may indirectly affect downstream activities in the signaling 
cascade, including phosphorylation of AKt and erK (8). We, 
therefore, recently tested the ability of the small molecule 
egFr competitive inhibitor Iressa to prevent urinary bladder 
tumor formation when administered either immediately 
following the last dose of oH-BBn, or 3 months following 
the last dose of oH-BBn when microscopic lesions, including 
tcc, already existed (1). It was found that Iressa (10 mg/kg 
BW/day, by gavage) was highly effective at either time-point; 
suggesting that the egFr inhibitor was effective late during 
the cancer progression process. In the present studies, these 
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findings were expanded to investigate the chemopreventive 
dose response of Iressa in this model, and to examine potential 
biomarkers that might give further insight into its mechanism 
of action. Also, the studies offer potential pharmacodynamic or 
efficacy biomarkers relevant to treatment with EGFr inhibitors 
in clinical trials. All biomarkers were examined in rats bearing 
large urinary bladder cancers that were treated for 5 days 
with Iressa. three different approaches were employed in the 
biomarkers studies: i) specific biomarkers directly associated 
with inhibition of egFr, including phosphorylated egFr, AKt 
and ERK; ii) non-specific proteins whose expressions were 
altered as assessed by employing 2-D gel electrophoresis and 
tandem mass spectroscopy; and iii) non-specific alterations in 
gene expression employing rnA microarray analyses. gene 
changes were examined both for altered expression of specific 
pathways, as well as identifying a wider group of genes 
whose expression was significantly altered. It was found that 
expression of cell cycle related genes were altered, including 
various cyclins, BUB1 and both Aurora kinases. these various 
modulated biomarkers may serve as pharmacodynamic and/
or efficacy indicators for treatment with this class of agents in 
clinical trails.
Materials and methods
For all studies, female Fischer-344 rats were obtained from 
Harlan sprague-Dawley, Inc. (Indianapolis, In). oH-BBn was 
purchased from tcI America (portland, or) and adminis-
tered by gavage (150 mg/dose, 2x/week for 8 weeks) beginning 
when the rats were 56 days of age. All animal experiments 
were conducted in facilities at the University of Alabama 
at Birmingham following the procedures approved by the 
Institutional Animal care and Use committee. Iressa was 
supplied by the national cancer Institute/Division of cancer 
prevention chemical repository.
Chemopreventive studies. For the dose-dependent study, Iressa 
treatment (either 4.5 or 1.5 mg/kg BW/day) was initiated one 
week after the final oH-BBn treatment (115 days of age). 
Iressa was administered by gavage daily (vehicle was ethanol: 
polyethylene glycol 400; 10:90; v/v). each gavage volume was 
0.5 ml. As previously reported (1), treatment with Iressa at a 
higher dose (10 mg/kg BW/day) was also given, but was initiated 
either 1 week or 3 months after the final OH-BBN treatment 
(rats were 195 days of age at time of initial treatment). All 
studies were terminated at 8 months after the initial carcinogen 
treatment. All bladder cancers were confirmed by histological 
evaluation. All rats were weighed 1x/week and palpated for 
urinary bladder tumors 2x/week as previously described (1,9). 
Rats were sacrificed when they developed a large bladder mass 
or at termination of the study. Individual weights of the urinary 
bladders plus lesions in each group were compared using 
Wilcoxon rank analysis. Differences between the incidence of 
large bladder tumors (weight of bladder plus lesions >200 mg) 
in the various groups were analyzed by χ2 analysis.
Biomarker studies
Generation of tissues. oH-BBn treated rats were allowed to 
develop a palpable lesion and were then treated for 5 days with 
Iressa (10 mg/kg BW/day) or with the vehicle. At sacrifice, the 
tumor was divided and either snap frozen in liquid nitrogen or 
placed in Zamboni's fixative.
Two-dimensional difference gel electrophoresis and image 
analysis of bladder cancers. Bladder tumors were prepared 
in a sample buffer (30 mM tris-Hcl pH 8.5, 7 M urea, 2 M 
thiourea, 4% cHAps) and labeled with 400 pmol of cy2, cy3 
or cy5. pools were prepared by mixing equal protein amounts 
of each sample following labeling. All samples were then 
equilibrated into immobilized pH gradient (Ipg) strips under 
100 V followed by isoelectric focusing using a maximum 
of 10,000 focusing volts (protean IeF cell, Bio-rad). After 
focusing, proteins were reduced with tcep (10 mM) and alky-
lated with iodoacetamide (20 mM). the Ipg strip was then 
layered on 10% polyacrylamide gels followed by sDs-pAge 
separation. samples were imaged with a typhoon Imager (ge 
Healthcare) using specific excitation/emission wavelengths: 
488/520 nm for cy2, 520/580 nm for cy3, 620/670 nm for cy5. 
the Decyder (ver. 6.5) software tools (ge Healthcare) were 
used for image analysis. the DIA (differential in-gel analysis) 
module was used to align and normalize images within each 
gel. spots with slopes >1.1, areas <100, volumes <10,000 and 
peak heights <100 were excluded. the DIA module calculated 
abundance ratios using a normalization algorithm that was 
applied as previously described (10). For comparative pair-
wise analyses of gel features across different physical gels, 
the DIA data sets were analyzed using the BVA (biological 
variation analysis) module. spot volumes were converted to 
ratios of a pooled internal standard. Using the extended data 
analysis (eDA) module, a t-test was performed to determine 
the statistical significance of ratios for each gel feature.
Protein identification of gel features using tandem mass 
spectrometry. gel features were excised robotically (propic, 
genomic solutions) using a triangulation algorithm imple-
mented with in-house software. the gel pieces were digested 
in situ with trypsin (11). samples were processed and analyzed 
using nano-lc-FtMs/Ms as previously described (12). the 
‘raw’ files were processed using MASCOT Distiller, version 
2.1.1.0 (Matrix science, oxford, UK) with the following 
settings: i) Ms processing, 200 data points per Da; no aggrega-
tion method; maximum charge state, +8; minimum number of 
peaks, 1. ii) Ms/Ms processing, 200 data points per Da; time 
domain aggregation method enabled; minimum number of 
peaks, 10; precursor charge and m/z, try to re-determine from 
the survey scan (tolerance, 2.5 Da); charge defaults, +2/+3; 
maximum charge state, +2. iii) time domain parameters, 
minimum precursor mass, 700; maximum precursor mass, 
16,000; precursor m/z tolerance for grouping, 0.1; maximum 
number of intermediate scans, 5; minimum number of scans in 
a group, 1. iv) peak picking, maximum iterations, 500; correla-
tion threshold, 0.90; minimum signal-to-noise, 3; minimum 
peak m/z, 50; maximum peak m/z, 100,000; minimum peak 
width, 0.001; maximum peak width, 2; and expected peak 
width, 0.01. the resulting Mascot generic files (mgf) were 
exported to MAscot, ver. 2.1.6. the tandem Ms data from 
the ltQ-Ft were searched against national center for 
Biotechnology Information non-redundant databases that were 
downloaded on 2008-11-26 with the following constraints: 
MS tolerance, 10 ppm, MS/MS tolerance, 0.8 Da with fixed 
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modifications of cysteine residues (carbamidomethylation) 
and variable oxidation of methionine residues. the resulting 
DAT files were imported into Scaffold, ver. 2.0 (Proteome 
Software, Portland, OR) to identify proteins with >95% confi-
dence and to determine the spectral counts for each protein. 
the network analysis was generated using Ingenuity pathways 
Analysis software, ver. 6.
IHC detection of phosporylated proteins. Immunohisto-
chemical detections of phosphorylation of egFr (tyr1173), 
erKs, Akt (ser473), total egFr and Ki67 were performed. 
Bladder tumors were excised and drop fixed in Zamboni's 
fixative [0.03% picric acid (w/v) and 2% paraformaldehyde 
(w/v)] for 48 h at 5˚C and then transferred to a 20% sucrose 
solution with 0.05% sodium azide in pBs for storage at 
5˚C. Processing and staining of tumors were carried out 
according to a published procedure (13). Whole tumors were 
cryosectioned into 80 mm sections. Floating sections were 
incubated first with the primary antibody, and then incubated 
in 1:10,0000 anti-goat Igg, conjugated to cy 3 (red color) 
or cy 5 (blue color) (Jackson Immuno research). Washed 
samples were mounted in agar, dehydrated in ethanol, cleared 
with methyl salicylate and mounted in DepeX (electron 
Microscopy science). optical sections were captured by laser 
scanning confocal microscopy.
RNA isolation and amplification. Bladder tumors were excised 
and frozen at -80˚C for subsequent molecular assays. A portion 
of each tumor was fixed, processed for paraffin embedding, 
cut into 5-µm sections, and mounted for hematoxylin and 
eosin (H&e) staining. All urinary bladder tumors used in 
this study were diagnosed as bladder cancers. total rnA 
from bladder tumors treated with Iressa were isolated by 
trIzol (Invitrogen, carlsbad, cA) and purified using the 
rneasy Mini Kit and rnase-free Dnase set (Qiagen, 
Valencia, cA) according to the manufacturer's protocol. In vitro 
transcription-based RNA amplification was then performed 
on each sample. cDnA for each sample was synthesized 
using a superscript cDnA synthesis Kit (Invitrogen) and a 
t7-(dt)24 primer: 5'-ggccAgtgAAttgtAAtAcgAct 
cActAtAgggAggcgg-(dt)24-3'. the cDnA was cleaned 
using phase-lock gel phenol/chloroform extraction (Fisher 
scientific). the biotin-labeled crnA was then transcribed 
in vitro from cDnA using a BioArray High yield rnA 
transcript labeling Kit (enZo Biochem, new york, ny) and 
purified, again using the RNeasy mini kit.
Affymetrix GeneChip probe array analysis. the labeled 
crnA was applied to the Affymetrix rat exon 1.0 st Array 
(Affymetrix, santa clara, cA) according to the manufacturer's 
recommendations. gene-level signal estimates for the cel 
files from the platform Rat Exon 1.0 ST Array were derived 
by quantile sketch normalization using Iterplier algorithm, 
as implemented with expression console v1.1.1 (http://
www.affymetrix.com/products services/software/specific/
expressionconsolesoftware.affx). A two-sample student t-test 
was used to identify differentially expressed genes (Degs) 
between groups. to adjust for the multiple testing in the study 
of high-dimensional microarray data, local false discovery 
rate (lFDr) were estimated which was implemented in r 
package fdrtool (http://www.r-project.org/) (14). the Degs 
were defined as genes with LFDR <0.05 and fold change >1.5 
between two groups.
After identification of DEGs, they are inputted into gene set 
enrichment analysis (gseA). gseA is a computational method 
that determines whether a set of genes shows statistically 
significant differences in expression between two biological 
states. this has proved successful in discovering molecular 
pathways involved in human diseases (http://www.broad.mit.
edu/gsea). Using the Kolmogorov-smirnov statistic, gseA 
assesses the degree of ‘enrichment’ of a set of genes (e.g., a 
pathway) in the entire range of the strength of associations 
with the phenotype of interest. It was used to identify a priori 
defined sets of genes that were differentially expressed (15,16). 
We used curated gene sets (c2) which contain genes in certain 
molecular pathways, and go gene sets (c5) which consist 
of genes annotated by the same go terms in the Molecular 
signature Database (MsigDB, http://www.broad.mit.edu/
gsea/msigdb/msigdb_index.html). Because of small sample 
sizes, gseA with gene set permutation option was performed. 
Selected gene sets identified from GSEA were then visualized 
with Metacore™ (http://www.genego.com/). Hierarchical 
clustering was performed as follows: For the selected genes, 
expression indexes were transformed across samples to an n 
(0,1) distribution using a standard statistical Z-transform. these 
values were inputted into the genecluster program of eisen 
et al (17), and genes were clustered using average linkage and 
correlation dissimilarity.
table I. Weights of urinary bladders with oH-BBn induced tumors in female Fischer-344 rats treated with Iressa.
treatmenta Urinary bladder + tumors (mg)b no. of urinary bladder weights >200 mgc
Iressa, 4.5 mg/kg BW/day 148±9 (55%↓)d 5/30 (17%)d
Iressa, 1.5 mg/kg BW/day 192±14 (42%↓) 10/30 (33%)d
none 332±39  20/29 (69%)
arats received oH-BBn beginning at 56 days of age. treatment with Iressa initiated at 115 days of age (i.e., 1 week after the last carcinogen 
treatment). bUrinary bladder weights were those observed at sacrifice of the rats (study terminated 8 months after initial OH-BBN treatment). 
Values are mean ± seM (number in parenthesis is percent decrease from controls). cValues represent the number of rats with urinary bladder 
weights >200 mg divided by the number of rats in that group. dValues were significantly different (p<0.05) from controls.
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Results
Effect of Iressa in prevention studies. Iressa was evaluated 
at two dose levels to determine the lowest effective dose in 
preventing the formation of urinary bladder cancers. Iressa 
administered at doses of 4.5 and 1.5 mg/kg BW/day, 7x/week, 
decreased the number of large urinary bladder cancers (weights 
of total bladder plus tumors >200 mg) from 69% in the controls 
to 17 and 33%, respectively (table I). Furthermore, when the 
time of appearance of the palpable urinary bladder tumors 
was graphed (Fig. 1A), the 4.5 mg/kg BW/day dose was highly 
effective both in increasing tumor latency and in preventing the 
development of large tumors. A previous study from our labora-
tory (1) had demonstrated that a higher dose of Iressa (10 mg/kg 
BW/day) was even more effective in preventing the development 
of large tumors (Fig. 1B and c). this dose of Iressa was highly 
effective in increasing latency and decreasing the incidence 
of palpable tumors when administered beginning 1 week or 3 
months after the last dose of OH-BBN. The efficacy seen in 
the late administration is particularly interesting because at 
the later point 70% of rats already had invasive carcinomas 
(Fig. 1c).
Effects of EGFr inhibitors on tumor related biomarkers. Based 
on the striking efficacy following late administration of Iressa, we 
examined the effects of limited treatment for 5 days on palpable 
bladder cancers with Iressa (10 mg/kg BW/day). three different 
approaches were employed to identify potential biomarkers.
Examination of EGFr pathway related biomarkers (Fig. 2). 
the primary focus of these studies was to examine the effect 
of Iressa on proteins associated with the egFr pathway 
including egFr and its downstream effector proteins AKt and 
erK. Using immunohistochemistry and confocal microscopy, 
it was found that levels of phosphorylated egFr (tyr1173), Akt 
(ser473) and erKs were decreased by 50, 75 and 47%, respec-
tively, in bladder cancers from rats receiving Iressa. these 
differences were found to be significant, and demonstrate the 
direct effects of Iressa on the egFr pathway.
Examination of the effects of Iressa on protein expression 
employing 2D gel (Fig. 3). In these studies, protein expression 
levels from Iressa treated and control tumors were measured by 
labeling with fluorometrically distinct cyanine dyes (18). In the 
image shown in Fig. 3A, the green colored gel features indicate 
proteins that are decreased in the treated samples. of the 1500 
gel features, roughly 200 were found to be changed outside of 
the 95% confidence percentile. The differential gel features 
were excised, digested with trypsin in situ, and the proteins 
identified from the fragmentation spectra of the peptides.
A three dimensional view of two proteins associated with 
the VEGF pathway [Annexin A2 and MAP kinase kinase 
(MAp2K)] were shown to be decreased 2.3- and 4.5-fold, 
respectively, in the tumors from treated rats. the complete set 
of differentially expressed proteins was analyzed for network 
and pathway associations using Ingenuity pathways Analysis. 
the VegF pathway exhibited decreases in Annexin A2 and 
MAp kinase kinase (Fig. 3B), but also showed decreases in 
nucleolin (ncl) and the small gtpase rho A; both of which 
also function in the VegF pathway.
Examination of the effects of Iressa on gene expression 
employing oligonucleotide microarrays (Figs. 4 and 5). In 
Figure 1. effects of Iressa on the time of appearance of palpable urinary 
bladder tumors in female Fischer-344 rats. (A) Iressa (4.5 and 1.5 mg/kg BW/
day) was administered from one week after the final OH-BBN treatment until 
the end of the study. ○, Iressa 4.5 mg/kg BW/day; ◻, Iressa 1.5 mg/kg BW/
day; ●, control. (B) effects of high dose Iressa (10 mg/kg BW/day) on time 
of appearance of palpable urinary bladder tumors in female Fischer-344 rats 
(1). Iressa was started one week after the final OH-BBN treatment. ○, Iressa 
10 mg/kg BW/day; ●, control (C). Iressa was started 3 months after the final 
oH-BBn treatment. ○, Iressa 10 mg/kg BW/day; ●, control.
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these studies, the effects of Iressa on gene expression by 
employing oligonucleotide microarrays were determined. 
As shown in Fig. 5, there were an extremely large number 
of genes whose expressions were altered when comparing 
bladder cancers treated short-term with Iressa and control 
bladder cancers. the resulting gene expression changes 
were examined using gene pathway analysis, and genes 
in several pathways were identified. the gene expression 
pathway analysis (Fig. 4) and accompanying expression 
levels (table II) of genes associated with cell cycle pathways 
[specifically, the anaphase protein complex (APC)] are 
presented. expression of various genes, including cyclins B 
and D, cDc20, BUBr1, BUB1, securin and Aurora B, were 
all substantially decreased in Iressa treated vs control bladder 
tumors. When expression of the genes coding for e cadherin 
and vimentin were compared in normal bladder epithelium 
and bladder tumors, cdh1 was modestly down-regulated in 
bladder tumors (lFDr=0.003 and fold change = -1.42); no 
difference in expression of Vim was found.
Discussion
Studies were performed to examine the efficacy of an EGFr 
inhibitor in the oH-BBn induced model of urinary bladder 
cancers, as well as to examine potential expression changes 
which might prove applicable as pharmacodynamic or effi-
cacy biomarkers in clinical trials using this class of agents. 
the tumors that develop in the oH-BBn induced model are 
primarily transitional cell or mixed cell carcinomas as defined 
by histopathology. In addition, they exhibit many changes 
found in human bladder cancers (3,4), including increased 
levels of survivin, gst pi, Annexin, various s-100 proteins, 
and decreased levels of FHIt. recently, we have compared 
urinary bladder tumors with normal bladder epithelium 
employing gene arrays (4). those results showed alterations in 
a variety of pathways including general overexpression of the 
genes related to the egFr pathway.
Based on the fact that egFr is expressed at higher levels 
in bladder tumors than in normal bladder epithelium (6,7), 
both in humans and in rats, the efficacy of Iressa was tested in 
the oH-BBn bladder cancer model. Iressa treatment initiated 
at one week following the last dose of oH-BBn yielded a 
dose-dependent decrease in the formation of urinary bladder 
cancers. Interestingly, the highest dose employed (10 mg/kg 
BW/day) is approximately 2x less than the typical human dose; 
based on a standard rat/human scaling factor (1). It was found 
that even lower doses of Iressa (4.5 and 1.5 mg/kg BW/day) 
were effective in preventing oH-BBn induced bladder tumors. 
More importantly, the highest dose of Iressa was highly effec-
tive in increasing tumor latency when administered beginning 
three months following the final dose of OH-BBN (Fig. 1C); at a 
time when 70% of animals had already developed microscopic 
invasive bladder lesions (1). Highly significant prevention at 
this late stage suggests that the effect of Iressa was primarily 
on the progression stage of the carcinogenic process. Based on 
these findings, various data with human bladder cancer cell 
cultures, and the finding that EGFr is overexpressed in many 
human bladder cancers support the use of an egFr inhibitor 
in an adjuvant setting in humans. In fact, the egFr inhibitors 
tarceva (egFr1) and lapatinib (egFr 1 and 2) have undergone 
small phase II trials in more advanced bladder cancers, and 
both appear to show activity (19,20).
the determination of potential biomarkers has multiple 
objectives. First, it may offer some mechanistic insights into 
the mode of action of a given agent or class of agents. Although 
in the case of Iressa, the primary target is clearly defined. 
Changes in specific pathways [e.g., VEGF (proteomics) or 
cell cycle (genomics)], may give insights into the molecular 
mechanism(s) underlying the efficacy of the agent. Second, 
since these changes are observed at a highly effective dose of 
Iressa, some of the observed changes may identify biomarkers 
related to the efficacy of the agent. However, even if these 
changes are primarily pharmacodynamic (implying pharma-
Figure 2. Immunostaining and quantitation of pegFr, total egFr, pAKt and 
perKs in urinary bladder tumors from untreated or Iressa treated rats (10 mg/kg 
BW/day for 5 days). (A) representative bladder cancers from untreated rats (left 
3 columns) or Iressa treated rats (right 3 columns). slides were immunolabeled 
with antibodies to detect specific proteins (top row, pEGFR; second from top, 
egFr; third from top, pAKt; bottom, perK). the image is a z-projection 
created from 30 1 µ sections using laser confocal microscopy (nikon clsi 
confocal spectral Imaging system, nikon Instrument company) with a cFI 
plan Fluorx 20x objective. (B) the light intensity of three different cancers 
was estimated using the Image J computer program; data shown as mean ± sD. 
Asterisk indicates decreased expression, p<0.05.
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Figure 3. proteomic analysis of urinary bladder cancers from Iressa-treated and control rats. (A) two-dimensional difference gel electrophoresis as described 
in Materials and methods. green spots are overexpressed in control tumors. red spots are overexpressed in Iressa-treated tumors. (B) topological mapping of 
two individual spots (Annexin A2, MAP2K1) after identification of peptides by mass spectrometry.
Figure 4. Effects of Iressa on cell cycle related genes associated with anaphase promoting complex (APC). Alterations in specific genes are based on 
Affymatrix analysis of gene expression (Materials and methods).
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Figure 5. gene showing changes in expression when comparing cancers from Iressa-treated and control rats. Data based on microarray analysis: red, overex-
pressed; green, underexpressed; black, average expression.
Table II. Significant changes in gene expression in cell cyle APC related pathway.
 Mean ± sD ---------------------------------------------------------------------
probe set ID gene control tumor treated tumor p-value lFDr Fold change
7290458 cDc20 372±113 124±70 0.000116 0.0056 3.01
7207681 ccnA2 522±194 198±162 0.002608 0.019895 2.64
7203074 ccnB1 425±124 162±121 0.000569 0.009926 2.62
7036458 plK1 691±253 249±177 0.001245 0.012326 2.77
7244612 BUB1 498±161 205±156 0.002007 0.015968 2.43
7231515 BUB1B 359±128 137±86 0.00118 0.012326 2.63
7076550 pttg1 207±77   81±55 0.002172 0.015968 2.55
7057437 KIF22 278±84 125±75 0.001485 0.012708 2.23
7248426 AUrKA 255±66 155±56 0.005007 0.027147 1.65
7068974 AUrKB 352±131 132±99 0.001997 0.015968 2.66
7258359 cDcA3 225±63   86±34 9.24e-05 0.004977 2.63
7218195 cDc2 224±59 110±74 0.003072 0.020887 2.03
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cologic/physiologic effects) for the agent, these biomarkers 
may be important to potential clinical prevention trials, 
particularly phase II trials. In examining the biomarker 
data, one must be aware that although Iressa can block 
further tumor development (even beginning at a time when 
established carcinomas exist), it has not been shown that it 
can cause the regression of existing large lesions. part of the 
problem is that we typically identify palpable lesions that are 
relatively large and that have invaded the underlying tissues. 
thus, a method should be developed that will permit the 
identification of smaller lesions in order to determine whether 
an egFr inhibitor is therapeutic in this model.
the first set of potential biomarkers examined was 
directly related to inhibition of phosphorylated egFr. 
Immunohistochemistry showed that Iressa induced significant 
decreases in amounts of phosphorylated egFr (tyr 1173)s, 
phosphorylated AKt (ser 473) and phosphorylated erKs. 
Interestingly, our laboratories have observed modulation of 
these same parameters in a mammary cancer model in which 
Iressa was similarly highly effective. In this case, the results 
were confirmed employing Western blot analyses. These studies 
parallel a pre-surgical model of cancer that could demonstrate 
the modulation of the expected targets of the inhibitor (8).
the second biomarker approach looked at potential 
changes in expression of various proteins of bladder cancers 
employing a 2D gel approach. proteins were extracted, 
labeled with cyanine dyes, separated by 2D electrophoresis, 
and the images were co-registered with software. the relative 
abundance of proteins in tumors of Iressa-treated rats can 
be determined without variability associated with aligning 
images from multiple 2D analyses. The verification of the 
approach is illustrated by the identification of proteins that are 
well recognized to be associated with the effects of the VegF 
pathway in tumor angiogenesis (Fig. 3). Annexin II is a tumor 
associated protein with a potential role in tumor progression 
and angiogenesis (21). the decrease in expression of MApK 
kinase, a protein associated with angiogeneis (22), suggests 
downstream effects of egFr inhibitors. In summary, these 2D 
gel findings are consistent with previous data indicating that 
alterations in the VegF pathway are associated with effects 
of the egFr inhibitors (23). these changes, as mentioned 
above, are probably secondary to the initial inhibition of 
egFr phosphorylation. nevertheless, changes in the angio-
genesis pathway may contribute to the overall efficacy that 
was observed.
Finally, gene expression oligonucleotide arrays were 
performed to determine which genes exhibit altered expres-
sion levels in bladder cancers from Iressa treated rats. 
Although gene expression is two steps removed from protein 
function and protein expression, it has many advantages; 
including the ability to examine simultaneously the widest 
variety of genes, and to integrate the results into pathways 
or functional analyses. numerous pathways were found to 
be altered (cell cycle, g-protein receptor, DnA damage and 
DnA repair). the genes associated with the anaphase protein 
complex pathway that were altered are presented in table II 
and Fig. 4. the changes were statistically significant and 
caused 2- to 4-fold decreases in gene expression. Included 
among these genes were ccnA2, cDc2, cDc20, cyclin 
B1 and Aurora kinases A and B. these differences support 
the finding of substantial decreases in proliferation in Iressa-
treated vs control bladder cancers (data not shown). the 
changes also correlate with the high efficacy of Iressa in this 
model of urinary bladder cancer (Fig. 1A and B). We also 
examined the expression of e cadherin (an epithelial cell 
marker) and vimentin (a mesenchymal cell marker) in normal 
urinary bladder epithelium and bladder cancers. the rationale 
being that tumors which have undergone a mesenchymal cell 
transition are less likely to respond to an egFr inhibitor. the 
minimal differences observed in expression of e cadherin and 
vimentin likely reflect a limited mesenchymal transition and 
may suggest that egFr inhibitors are highly effective; even 
at the later stages of progression. We feel that these potential 
biomarkers may be useful in clinical prevention or in adjuvant 
trials with this class of agents. one would not expect that 
most or all of the biomarkers from a rat would translate into a 
human, although the biomarkers directly related to the egFr 
phosphorylation pathway (egFrp, Aktp and erKp) are likely 
to be relevant across species. Furthermore, more complete 
analyses of the results from the 2D gels and gene arrays may 
yield a wide variety of potential biomarkers, of which some 
significant number are likely to be relevant to humans.
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